FDA Expands The Use Of Rituxan Treatment For NHL Patients

Thursday, March 1, 2007

FDA ExpandsThe Use Of Rituxan Treatment For NHL Patients (NAPSA)—There’s encouraging news for patients diagnosed with LymphomaFacts a form of cancer that affects the lymphatic system known as non- NHL is a concer that affects the lymphatic system. U.S. Food and Drug Administra- NHL is one of the mostrapidly increasing types of cancerin the U.S. Hodgkin’s lymphoma (NHL): The tion (FDA) has approved two additional uses for Rituxan (Rituximab) for patients with CD20positive, B-cell NHL. About NHL An estimated 360,000 Americans have NHL. Of those diagnosed, 31 percent have diffuse large B-cell lymphoma (DLBCL), a faster-growing subtype of NHL. About 30 percent have a slow-growing butincurable (low-grade) form of the disease—the most common type, called follicular lymphoma (FL). Although FL progresses slowly, the median survival time is seven to 10 years. In addition, relapse is common andless than half of FL patients who experience a relapse will survive for five years, underscoring the need for treatments that delay disease progression, relapse or death. “The goal of treating low-grade, or follicular, NHL, a chronic cancer marked by multiple recurrences, is to delay disease progression for as long as possible,” said Howard Hochster, M.D., professor of medicine and clinical pharmacology, New York University School of Medicine and CancerInstitute. New Indications The first new indication for Rituxan is for first-line treatmentof previously untreated patients with follicular NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. The secondis for the treatment of low-grade NHL in patients with stable disease or who achieve a partial or complete response followingfirst-line treat- ment with CVP chemotherapy. Currently, NHL is the sixth most fatal cancer in the U.S. More than 58,000 new cases of NHL are diagnosed annually. The two most commontypes of NHL are diffuse large B-cell lymphoma and follicular lymphoma. @ “These approvals enable doctors and patients to select among differ- ent treatment options using Ri- tuxan with or following CVP in the front-line setting,” said Hochster. Clinical Studies The FDA approval of Rituxan as a first-line treatment in previ- ously untreated patients with follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy is based on data from a PhaseIII, randomized, controlled study. The study evaluated the first-line use of Rituxan in combination with CVP chemotherapy versus CVP chemotherapy alone. Results indicated that: Rituxan plus CVP improved median progression-free survival to 2.4 years from 1.4 years for CVP chemotherapyalone. Rituxan plus CVP reduced the risk of disease progression, relapse or death by 56 percent comparedto CVP chemotherapy alone (hazard ratio = 0.44 p

--- PHOTOS ---

File: 20190731-153720-20190731-153717-70587.pdf.jpg

--- FILES ---

File: 20190731-153717-70587.pdf